Companies: 10,795·Total market cap: $144.5T

Kalaris Therapeutics Inc

Kalaris Therapeutics Inc

KLRSNASDAQHealthcare● Active

$4.17

$-0.27(-6.08%)

Market Cap$77990242

P/E Ratio—

52W High$11.88

52W Low$2.14

Avg Volume82K

Open$4.54

Beta0.14

股票排行：Biotechnology·Healthcare·查看全部市值排行 →

Kalaris Therapeutics Inc（KLRS）股票概览

关键指标与盈利、估值、营收、股息等标签页深链。

FMP · KLRS · 截至 Jun 9, 2026

关键指标

EPS (TTM)$-2.15Earnings history

PE Ratio (TTM)—PE Ratio deep dive

Revenue (TTM)0.00Full revenue history

Dividend Yield不分红Dividend history

Shares Outstanding15.3MShares outstanding history

Next EarningsAug 12, 2026Est.Earnings history

探索 Kalaris Therapeutics Inc 数据

分析师预测$18 · Buy

股息不分红

盈利EPS $-2.85+75.70%

财务快照

FY 2025Revenue$0.00

202320242025

FY 2025Net Income-$43.4M▲ +26.09% YoY

202320242025

FY 2025EPS$-2.85▲ +75.70% YoY

202320242025

TTM:Revenue: $0.00Net Income: -$44.1MEPS: $-2.15View income statement →

分析师评级与目标价

Buy1 位分析师

Strong Buy

0

Buy

1

Hold

0

Sell

0

Strong Sell

0

12-Month Price Target

$14.00Low

$4.17Current

$18.25Avg Target上涨空间 337.65%

$23.00High

合计: 1 · 买入占比: 100.0%

根据过去 3 个月内 1 位华尔街分析师，KLRS 共识评级为 Buy，12 个月平均目标价 $18.25 （较现价 $4.17 上涨空间 337.65%）。

竞争对手与同行

#TickerCompanyPriceChangeMkt Cap

Kalaris Therapeutics Inc

$4.17-6.08%$78.0M #2

Artiva Biotherapeutics, Inc.

$6.80-0.73%$168.1M #3

Connect Biopharma Holdings Limited

$2.20+1.38%$138.5M #4

Context Therapeutics Inc.

$1.71-2.29%$157.1M #5

$1.71-7.07%$123.5M #6

$5.63-0.35%$63.5M

股票表现

1D-6.08%

1W-11.65%

1M-17.91%

3M-58.30%

YTD-50.59%

1Y+36.27%

5Y-99.96%

关于 Kalaris Therapeutics Inc

CEOAndrew Oxtoby

IPO DateJul 30, 2020

Employees14

CountryUS

Websitekalaristx.com

Kalaris Therapeutics Inc operates as a pharmaceutical enterprise. The company's core mission centers on developing innovative cell therapies. These treatments are designed to reactivate the body's in…

Biotechnology HealthcareNASDAQUS

关于股票概览与关键数据

Kalaris Therapeutics Inc（KLRS）是 Biotechnology 行业的 Healthcare 类公司，于 Jul 30, 2020 在 NASDAQ 上市。截至最近交易日，KLRS 股价为 $4.17，市值约为 $78.0M。过去12个月累计回报 +36.27%，年初至今回报 -50.59%。

根据 1 位华尔街分析师，Kalaris Therapeutics Inc 股票共识评级为Buy，12个月平均目标价为 $18.25。2025 财年 Kalaris Therapeutics Inc 营收 —，净利润 -$43.4M。更多数据（营收历史、盈利、股息、市盈率）请使用上方标签页。

常见问题

截至最近一个交易日，Kalaris Therapeutics Inc（KLRS）股价为 $4.17，在 NASDAQ 上市，52周区间为 $2.14 – $11.88。

KLRS 最新股价KLRS quote todaylive ticker 实时行情

数据来源：Financial Modeling Prep最后更新：Jun 9, 2026本内容不构成投资建议